To evaluate the efficacy and safety of Disitamab vedotin (RC48-ADC) in patients with breast cancer.
Study Type
OBSERVATIONAL
Enrollment
45
recommended but not required regimen of 2.0mg/kg, iv, day1, every 2 weeks
Renji Hospital, School of Medicine, Shanghai Jiaotong University
Shanghai, China
RECRUITINGProgression-Free Survival
The time from the date of starting Disitamab Vedotin to the date of disease progression as per RECIST version 1.1 or death from any cause, whichever occurs first.
Time frame: From the date of starting Disitamab vedotin to the date of first documentation of progression or death (up to approximately 1 years)
Adverse events
Adverse events during Disitamab Vedotin regimen will be assessed according to the NCI CTCAE v5.0.
Time frame: From the date of starting Disitamab vedotin to the end of the treatment (up to approximately 1 year)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.